RO 7198457

Drug Profile

RO 7198457

Alternative Names: RO-7198457

Latest Information Update: 28 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioNTech
  • Developer BioNTech; Genentech
  • Class Antineoplastics; Cancer vaccines; RNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 21 Sep 2017 Preclinical trials in Cancer in USA (IV) (NCT03289962)
  • 21 Sep 2017 Genentech plans a phase Ia/Ib trial in Cancer (Monotherapy, Combination therapy) in USA, Belgium, Canada, Germany, the Netherlands, Spain, Sweden and United Kingdom (NCT03289962; 700288899)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top